. 2015 Nov 12;106(12):1722–1729. doi: 10.1111/cas.12827

Table 2.

Cox regression analysis for clinical outcome of anti‐epidermal growth factor receptor (EGFR) therapy for colorectal cancer

Variable	Univariate				Multivariate
	PFS		OS		PFS		OS
	HR (95% CI)	P‐value^†	HR (95% CI)	P‐value^†	HR (95% CI)	P‐value^†	HR (95% CI)	P‐value^†
Methylation status (LMCC versus HMCC)	0.23	<0.001	0.25	<0.001	0.23	<0.001	0.35	0.006
Methylation status (LMCC versus HMCC)	(0.14–0.38)	<0.001	(0.12–0.50)	<0.001	(0.13–0.41)	<0.001	(0.16–0.74)	0.006
Infrequent‐RAS mutation status (wild versus mutant)	0.54	0.100	0.32	0.010	0.84	0.64	0.37	0.030
Infrequent‐RAS mutation status (wild versus mutant)	(0.29–1.13)	0.100	(0.15–0.76)	0.010	(0.44–1.80)	0.64	(0.17–0.91)	0.030
Primary site (distal versus proximal)	0.83	0.430	0.55	0.080	1.08	0.78	0.64	0.210
Primary site (distal versus proximal)	(0.53–1.34)	0.430	(0.30–1.08)	0.080	(0.65–1.83)	0.78	(0.33–1.31)	0.210
No. of previous regimens (one or less versus two or more)	0.73	0.290	0.44	0.080	0.85	0.61	0.48	0.150
No. of previous regimens (one or less versus two or more)	(0.38–1.29)	0.290	(0.13–1.10)	0.080	(0.43–1.54)	0.61	(0.14–1.26)	0.150
Type of anti‐EGFR treatment (combination with irinotecan versus monotherapy)	0.53	0.010	0.64	0.270	0.57	0.03	0.59	0.220
	(0.34–0.87)	0.010	(0.31–1.45)	0.270	(0.35–0.96)	0.03	(0.28–1.39)	0.220
BRAF mutation status (wild versus mutant)	0.96	0.940	0.94	0.930	0.97	0.95	0.88	0.870
BRAF mutation status (wild versus mutant)	(0.42–2.82)	0.940	(0.28–5.80)	0.930	(0.41–2.89)	0.95	(0.23–5.51)	0.870

^†χ² test. CI, confidence interval; HMCC, highly methylated colorectal cancer; HR, hazard ratio; LMCC, low methylated colorectal cancer; OS, overall survival; PFS, progression‐free survival.